New disturbing trend in antimicrobial resistance of gram-negative pathogens

PLoS Pathogens

Volumn 5, Issue 3, 2009, Pages

  Lee, Jung Hun ^a   Jeong, Seok Hoon ^b   Cha, Sun Shin ^c   Lee, Sang Hee ^a  

^a Myong Ji University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Korea Research Institute of Ships and Ocean Engineering   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ASPERGILLUS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; ENZYME STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NOTE; PSEUDOMONAS AERUGINOSA; ARTICLE; BACTERIAL INFECTION; CHEMISTRY; CLASSIFICATION; DRUG DEVELOPMENT; ENZYMOLOGY; HUMAN; PHYSIOLOGY;

NEGIBACTERIA;

BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG DISCOVERY; GRAM-NEGATIVE BACTERIA; HUMANS;

EID: 63449092015     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000221     Document Type: Note

References (34)

1. Chopra I, Schofield C, Everett M, O'Neill A, Miller K, et al. (2008) Treatment of health-care-associated infections caused by Gram-negative bacteria: A consensus statement. Lancet Infect Dis 8: 133-139.
2. Thomson JM, Bonomo RA (2005) The threat of antibiotic resistance in Gram-negative pathogenic bacteria: Beta-lactams in peril! Curr Opin Microbiol 8: 518-524.
3. Kim C, Hesek D, Zajicek J, Vakulenko SB, Mobashery S (2006) Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3″)-Ii/AAC(6')-IId from Serratia marcescens. Biochemistry 45: 8368-8377.
4. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, et al. (2006) Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12: 83-88.
5. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, et al. (2007) Novel plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 51: 3354-3360.
6. Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, et al. (2007) Anti-infective research and development-Problems, challenges, and solutions. Lancet Infect Dis 7: 68-78.
7. Paterson DL, Bonomo RA (2005) Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 18: 657-686.
8. Nukaga M, Haruta S, Tanimoto K, Kogure K, Taniguchi K, et al. (1995) Molecular evolution of a class C β-lactamase extending its substrate specificity. J Biol Chem 270: 5729-5735.
9. Morosini MI, Negri MC, Shoichet B, Baquero MR, Baquero F, et al. (1998) An extended-spectrum AmpC-type β-lactamase obtained by in vitro antibiotic selection. FEMS Microbiol Lett 165: 85-90.
10. Crichlow GV, Kuzin AP, Nukaga M, Mayama K, Sawai T, et al. (1999) Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38: 10256-10261.
11. Barnaud G, Labia R, Raskine L, Sanson-Le Pors MJ, Philippon A, et al. (2001) Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 195: 185-190.
12. Thomson KS, Moland ES (2000) Version 2000: The new β-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect 2: 1225-1235.
13. Bae IK, Lee YN, Jeong SH, Hong SG, Lee JH, et al. (2007) Genetic and biochemical characterization of GES-5, an extended-spectrum class A β-lactamase from Klebsiella pneumoniae. Diagn Microbiol Infect Dis 58: 465-468.
14. Poirel L, Héritier C, Podglajen I, Sougakoff W, Gutmann L, et al. (2003) Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother 47: 755-758.
15. Poirel L, Gniadkowski M, Nordman P (2002) Biochemical analysis of ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 50: 1031-1034.
16. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P (2004) Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 48: 716-720.
17. Mammeri H, Poirel L, Fortineau N, Nordmann P (2006) Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob Agents Chemother 50: 2573-2576.
18. Mammeri H, Poirel L, Nordmann P (2007) Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 60: 490-494.
19. Mammeri H, Nazic H, Naas T, Poirel L, Leotard S, et al. (2004) AmpC β-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 48: 4050-4053.
20. Thomson KS (2001) Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis 7: 333-336.
21. Hanson ND (2003) AmpC β-lactamases: What do we need to know for the future? J Antimicrob Chemother 52: 2-4.
22. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, et al. (2006) Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657-668.
23. Munoz-Price LS, Weinstein RA (2008) Acinetobacter infection. N Engl J Med 358: 1271-1281.
24. Kim JY, Jung HI, An YJ, Lee JH, Kim SJ, et al. (2006) Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol Microbiol 60: 907-916.
25. Anderson AC (2002) The process of structure-based drug design. Chem Biol 10: 787-797.
26. Powers RA, Morandi F, Shoichet BK (2002) Structure-based discovery ofa novel, noncovalent inhibitor of AmpC β-lactamase. Structure 10: 1013-1023.
27. Fox JL (2006) The business of developing antibacterials. Nat Biotechnol 24: 1521-1528.
28. Matsumura N, Minami S, Mitsuhashi S (1998) Sequences of homologous β-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrob Agents Chemother 42: 176-179.
29. Hidri N, Barnaud G, Decre D, Cerceau C, Lalande V, et al. (2005) Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate. J Antimicrob Chemother 55: 496-499.
30. Barnaud G, Benzerara Y, Gravisse J, Raskine L, Sanson-Le Pors MJ, et al. (2004) Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 48: 1040-1042.
31. Doi Y, Wachino J, Ishiguro M, Kurokawa H, Yamane K, et al. (2004) Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob Agents Chemother 48: 2652-2658.
32. CMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob Agents Chemother 50: 534-541.
33. Vakulenko SB, Golemi D, Geryk B, Suvorov M, Knox JR, et al. (2002) Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother 46: 1966-1970. 34. Barlow M, Hall BG (2003) Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC β-lactamase. Genetics 164:23-29.
34. Raimondi A, Sisto F, Nikaido H (2001) Mutation in Serratia marcescens AmpC β-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob Agents Chemother 45:2331-2339.